Market Research Logo

Biological Therapies for Cancer: Technologies and Global Markets

Biological Therapies for Cancer: Technologies and Global Markets

REPORT HIGHLIGHTS

The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.

This report provides:

An overview of the global markets and technologies for biological therapies for cancer

Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.

Detailed analyses of products in the market, market structure and competitive environments, cancer markets in newly emerging therapeutics, and analysis of biosimilars and their impact on the market.

Details concerning the strengths, weaknesses, opportunities, and threats facing various cancer biotherapeutics already on the market.

A look at major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.

Comprehensive profiles of major players in the cancer biotherapeutics field.


SCOPE AND FORMAT

This report provides an update on BIO048B Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2019. It discusses important biologics, market share by cancer type, products on the market, market share by company, statistical information for cancer types prevalent globally, with special emphasis on the U.S. market. It also includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.

The market and sales data for various years gives strong support for the research and development (R&D) program and the move toward biologic treatment for cancer, as well as within biologic toward human monoclonal antibodies, vaccines and interferons. The biologic drug classes discussed in this report with special focus on cancer treatment are:
Monoclonal antibodies.
Vaccines.
Erythropoietin.
Colony stimulating factors.
Interleukins and interferons.

The following approaches to cancer therapeutics are excluded in the report:

Chemotherapy.
Alkylating agents.
Antimetabolites.
Cytotoxic agents.
Plant derivatives and hormone therapy corticosteroids.
Hormone antagonists/antagonists aromatase inhibitors.
Radiation therapy.
Adjunctive therapy.

Biological therapies for treatment of other diseases will not be addressed in this report.

The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:
Treatment trends and sales patterns across major cancer indications for Japan, Europe E.U.5 nations (i.e., France, Germany, Italy, Spain, the U.K.), the U.S. and the rest of the world (ROW).
Market performance of major pharmaceutical companies.
Forecast sales of leading products across major indications to 2019.
Biosimilars and their impact on currently marketed cancer biotherapeutics.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE AND FORMAT
INTENDED AUDIENCE
METHODOLOGY
RELATED BCC RESEARCH REPORTS
ANALYST'S CREDENTIALS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
SUMMARY FIGURE GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, 2008-2019 ($ MILLIONS)
CHAPTER 3 BIOLOGICAL TREATMENTS FOR CANCER
DEFINING CANCER
CAUSES OF CANCER GROWTH
CANCER TREATMENT STRATEGIES
COMMON TREATMENTS AND PROBLEMS
Surgery
Chemotherapy
Radiation Treatment
Targeted Therapy
Hormone Therapy
BIOLOGICAL THERAPY OF CANCER
CHAPTER 4 CANCER DESCRIPTIONS
TABLE 1 MAIN CANCER CATEGORIES
LUNG CANCER
LUNG CANCER TREATMENT
BIOLOGIC USE
BLADDER CANCER
BREAST CANCER
HER2 EXPRESSION
Antiangiogenic and HER2 Agents
CERVICAL CANCER
VACCINES
DIAGNOSIS
TREATMENT
Avastin
COLORECTAL CANCER
SMALL INTESTINE CANCER
ESOPHAGEAL CANCER
KIDNEY CANCER
TARGETED THERAPIES FOR KIDNEY CANCER
TABLE 2 APPROVED RENAL CELL CANCER DRUGS
Sorafenib
Sunitinib
Temsirolimus
Everolimus
Bevacizumab
Pazopanib
Axitinib
LEUKEMIA
SYMPTOMS AND TREATMENT
LYMPHOMA
NON-HODGKIN'S LYMPHOMA
TABLE 3 MONOCLONAL ANTIBODIES FOR NON-HODGKIN'S LYMPHOMA
TREATMENT
Extranodal B-cell Lymphoma of Mucosa Associated Lymphoid Tissue
Mantle Cell Lymphoma
Mediastinal Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma
LIVER CANCER
MELANOMA
METASTATIC MELANOMA
MULTIPLE MYELOMA
BRAIN CANCER
TABLE 4 BRAIN TUMOR SPECIFIC STATISTICS
GLIOMAS
TABLE 5 ASTROCYTOMAS
MENINGIOMAS
ACOUSTIC NEUROMAS AND SCHWANNOMAS
MEDULLOBLASTOMA
OVARIAN CANCER
DIAGNOSIS
PANCREATIC CANCER
PROSTATE CANCER
STOMACH CANCER
TABLE 6 STOMACH CANCER TYPES
TABLE 7 ADENOCARCINOMA STOMACH CANCER STAGES
CLINICAL TRIALS
HEAD AND NECK CANCERS
TABLE 8 HEAD AND NECK CANCER TYPES
CHAPTER 5 PRODUCT SEGMENTS AND TECHNOLOGY
TABLE 9 GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 1 GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, 2008-2019 ($ MILLIONS)
MONOCLONAL ANTIBODIES
TABLE 10 MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
MONOCLONAL ANTIBODIES: RECENT MARKET ACTIVITIES AND TRENDS
THE FUTURE OF CANCER MONOCLONALS
TABLE 11 ANTIBODY-BASED DEVELOPMENTS WITH EPITHELIAL
CELL-ADHESION MOLECULE
MONOCLONALS ON THE MARKET
Rituxan
TABLE 12 GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014 ($ MILLIONS)
FIGURE 2 GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014 ($ MILLIONS)
TABLE 13 U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009 ($ MILLIONS)
FIGURE 3 U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009 ($ MILLIONS)
Avastin
Herceptin
Campath
Erbitux
TABLE 14 ERBITUX APPROVALS
Approved for KRAS Wild-Type, Epidermal Growth Factor
Receptor-Expressing Metastatic Colorectal Cancer
Approved for Recurrent or Metastatic Head and Neck Cancers
Head and Neck Cancers
Colorectal Cancer
Mylotarg
Vectibix
Bexxar
Zevalin
INTERFERONS
TABLE 15 GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014 ($ MILLIONS)
FIGURE 4 GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014 ($ MILLIONS)
ALDESLEUKIN
INTERFERON ALPHA
VACCINES
THERAPEUTIC AND PREVENTATIVE CANCER VACCINES
PREVENTIVE CANCER VACCINES
TABLE 16 GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014 ($ MILLIONS)
FIGURE 5 GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014 ($ MILLIONS)
Gardasil
GRANULOCYTE COLONY STIMULATING FACTOR
TABLE 17 GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014 ($ MILLIONS)
FIGURE 6 GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014 ($ MILLIONS)
ARANESP
PROCRIT AND EPOGEN
OMONTYS
NEULASTA
NEUPOGEN
LEUKINE/SARGRAMOSTIM
NEUMEGA
BIOSIMILARS
BIOCON
OTHER BIOTHERAPY AND GENE THERAPY
CHAPTER 6 MARKET DYNAMICS AND OVERVIEW
TABLE 18 GLOBAL BIOLOGICS SALES, 2013 ($ MILLIONS)
PIPELINE BIOLOGICS
STANDARD TREATMENTS
GLOBAL CANCER MARKET TRENDS
TABLE 19 GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030 (MILLIONS)
FIGURE 7 GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030 (MILLIONS)
TABLE 20 GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION,
2007-2030 (MILLIONS)
FIGURE 8 GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007-2030 (MILLIONS)
TABLE 21 APPROVED ONCOLOGY DRUGS, 2013-2014
GLOBAL ONCOLOGY MARKET
TABLE 22 GLOBAL ONCOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 9 GLOBAL ONCOLOGY MARKET BY REGION, 2008-2019 ($ MILLIONS)
PAST PERFORMANCE OF CANCER DRUGS
TABLE 23 GLOBAL ONCOLOGY SALES, 2012 AND 2013 ($ MILLIONS/%)
EMERGING MARKETS
TABLE 24 ASIA-PACIFIC SOLID TUMOR MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 25 ASIA-PACIFIC ONCOLOGY MARKET, 2008 ($ MILLIONS)
FIGURE 10 ASIA-PACIFIC ONCOLOGY MARKET, 2008 ($ MILLIONS)
GLOBAL CANCER BIOLOGICAL THERAPEUTIC MARKET
TABLE 26 GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2019 ($ MILLIONS)
FIGURE 11 GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2008-2019 ($ MILLIONS)
TABLE 27 U.S. BIOLOGIC DRUG SALES, 2011 AND 2012 ($ BILLIONS)
CANCER BIOTHERAPEUTIC MARKET SIZE AND GROWTH
TABLE 28 GLOBAL BIOLOGICAL MONOCLONAL, ANTIBODY CANCER TREATMENT MARKET, THROUGH 2019 ($ MILLIONS)
FIGURE 12 GLOBAL BIOLOGICAL MONOCLONAL ANTIBODY MARKET, 2009-2019 ($ MILLIONS)
TABLE 29 CANCER MONOCLONAL ANTIBODY THERAPIES
NEW DEVELOPMENTS
ARZERRA
NIVOLUMAB
TABLE 30 GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, THROUGH 2019 ($ MILLIONS)
FIGURE 13 GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, 2013-2019 ($ MILLIONS)
BEXXAR
ZEVALIN
SANOFI/GENZYME WITHDRAWS CAMPATH
PROMETHEUS ACQUIRES EXCLUSIVE RIGHTS TO PROLEUKIN IN THE U.S.
TABLE 31 SELECTED INTERFERON DRUG SALES, 2009 ($ MILLIONS)
ROCHE
TABLE 32 PATENT EXPIRIES
Gazyva
JOHNSON AND JOHNSON
TABLE 33 REMICADE SALES, 2012-2014 ($ MILLIONS)
Procrit
TABLE 34 PROCRIT SALES, 2009 AND 2012 ($ MILLIONS)
MERCK AND BRISTOL-MYERS SQUIBB
CANCER VACCINES
TABLE 35 GLOBAL BIOLOGICAL CANCER VACCINE MARKET, THROUGH 2019 ($ MILLIONS)
FIGURE 14 GLOBAL BIOLOGICAL CANCER VACCINE MARKET, 2009-2019 ($MILLIONS)
TABLE 36 GARDASIL SALES, 2012 AND 2013 ($ MILLIONS)
PFIZER
TABLE 37 MYLOTARG SALES, 2009 ($ MILLIONS)
TABLE 38 GLOBAL IMMUNOSTIMULANT MARKET, THROUGH 2019 ($ MILLIONS)
FIGURE 15 GLOBAL IMMUNOSTIMULANT MARKET, 2009-2019 ($ MILLIONS)
TABLE 39 AMGEN SALES, 2012-2013 ($ MILLIONS)
ISSUES AND TRENDS AFFECTING THE MARKET
CHAPTER 7 PRODUCTS IN DEVELOPMENT
RECENT DEVELOPMENTS AND APPROVALS
TABLE 40 APPROVED BIOLOGICS CANCER DRUGS, 2013-2014
2013 APPROVALS
NEW DRUGS AND COMPANIES IN DEVELOPMENT
ROCHE'S GAZYVA
AMGEN'S PROLIA
PFIZER'S TANEZUMAB
PEREGRINE'S COTARA
DENDREON'S PROVENGE
TABLE 41 PROVENGE'S KEY FEATURES
CEL-SCI'S MULTIKINE
NORTHWEST BIOTHERAPEUTICS
GERON
TABLE 42 GERON-SPONSORED CLINICAL TRIALS
ADVAXIS
TABLE 43 ADVAXIS DRUG CANDIDATES
AGENUS
ONCOTHYREON
IMMUNOCELLULAR THERAPEUTICS
INOVIO BIOMEDICAL
BIOVEST
OMNIMMUNE
CELLDEX THERAPEUTICS
CDX-1127
ONCOLYTICS BIOTECH
TABLE 44 ONCOLYTICS BIOTECH CLINICAL TRIALS
CLINICAL TRIALS
VICAL
PIPELINE DRUGS IN DEVELOPMENT
ABT-199/GDC-0199
TABLE 45 ABBVIE ONCOLOGY PIPELINE
ELOTUZUMAB
ABT-414
ABT-700
XBIOTECH
TABLE 46 ENROLLING OR COMPLETED CLINICAL STUDIES*
PFIZER ONCOLOGY
TABLE 47 PFIZER ONCOLOGY PIPELINE
CLINICAL TRIALS IN ONCOLOGY
TABLE 48 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER)
FIGURE 16 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER)
TABLE 49 APPROVED BIOLOGICS FOR CANCER, 2009
CONCLUSIONS
CHAPTER 8 ONCOLOGY DRUG MARKET
MARKET SIZE AND GROWTH
MARKET BY PRODUCT TYPE
Roche
Kadcyla (ado-trastuzumab emtansine)
Perjeta
Rituxan
TABLE 50 RITUXAN TREATMENT INDICATIONS
Avastin
Herceptin
Neulasta
Amgen
Xgeva
TABLE 51 DENOSUMAB MARKET, THROUGH 2019 ($ MILLIONS)
Aranesp
ONCOLOGY MARKET AND GROWTH
TABLE 52 TOP CANCER BIOLOGICS, 2007-2009 ($ MILLIONS)
FIGURE 17 TOP CANCER BIOLOGICS, 2007-2009 ($ MILLIONS)
MARKET BY REGION
TABLE 53 ONCOLOGY TREATMENT BY REGION, 2013
Oncology Pipeline
U.S. Cancer Market
TABLE 54 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
FIGURE 18 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
TABLE 55 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2007-2009
TABLE 56 CAMPATH SALES, 2007 AND 2008 ($ MILLIONS)
Japanese Cancer Market
TABLE 57 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
FIGURE 19 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
TABLE 58 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
FIGURE 20 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
European Cancer Market
TABLE 59 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
FIGURE 21 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
TABLE 60 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
Asia-Pacific Cancer Market
Australian Cancer Market
South Korean Cancer Market
Chinese Cancer Market
Indian Cancer Market
Singapore Cancer Market
Taiwanese Cancer Market
BIOMAb-EGFR
TABLE 61 ASIA-PACIFIC ONCOLOGY COMPANIES
MARKET DATA BY TOP-SELLING BIOLOGIC DRUGS
TABLE 62 GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
FIGURE 22 GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
TABLE 63 U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ ILLIONS)
FIGURE 23 U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
CHAPTER 9 GLOBAL CANCER STATISTICS
GLOBAL CANCER INCIDENCE
CANCER TRENDS
TABLE 64 CANCER ESTIMATES, 2012 (MILLIONS)
TABLE 65 NEW CANCER CASES DIAGNOSED, 2012* (NUMBER/%)
TABLE 66 GLOBAL COMMONLY DIAGNOSED CANCERS, 2012 (MILLIONS/%)
TABLE 67 AGE-STANDARDIZED CANCER RATES, 2012 (PER 100,000)
TRENDS OVER TIME
GLOBAL CANCER INCIDENCE, 2008
TABLE 68 GLOBAL CANCER INCIDENCE BY TYPE, 2008 (MILLIONS)
TABLE 69 GLOBAL CANCER DEATHS BY TYPE, 2008 (MILLIONS)
TABLE 70 GLOBAL CANCER DISTRIBUTION BY TYPE, 2009 (MILLIONS)
TABLE 71 GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2009 (MILLIONS)
FUTURE TRENDS, 2020
TABLE 72 NEW CANCER CASES BY TYPE, 2020 (MILLIONS)
TABLE 73 GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2020 (MILLIONS)
CANCER CURE AND COSTS
RISE IN CANCER: CAUSES
TABLE 74 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
PROJECTIONS TO 2030
TABLE 75 GLOBAL CANCER INCIDENCE, 2008-2030 ($ MILLIONS)
FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030 (MILLIONS)
TABLE 76 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009 MILLIONS/%)
FIGURE 25 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009 (%)
CURRENT CANCER TRENDS AND ECONOMIC BURDEN
TABLE 77 GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008 (MILLIONS)
FIGURE 26 GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008 (MILLIONS)
TABLE 78 GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012
FIGURE 27 GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012 (MILLIONS)
TABLE 79 GLOBAL MORTALITY BY CANCER TYPE, 2012 (MILLIONS)
CANCER PREVALENCE AND MARKET
EMERGING MARKETS
Africa
Asia
China
Malaysia
India
Europe
Americas
TABLE 80 AMERICAS: CANCER FACTS
North America
TABLE 81 U.S. LEADING NEW CANCER CASES, 2014 (NUMBER/%)
TABLE 82 U.S. LEADING NEW CANCER CASES, 2014 (NUMBER/%)
TABLE 83 U.S. CANCER INCIDENCE BY TYPE, 2007-2009
FIGURE 28 U.S. CANCER INCIDENCE BY TYPE, 2007-2009
(MILLIONS)
TABLE 84 U.S. CANCER DEATHS BY TYPE, 2007-2009 (MILLIONS)
FIGURE 29 U.S. CANCER DEATHS BY CANCER TYPE, 2007-2009 (MILLIONS)
Canada
CHAPTER 10 BIOLOGIC CANCER MARKET ISSUES AND TRENDS
MEDICARE AND HEALTHCARE POLICIES
CANCER COSTS
CANCER DRUG COSTS
PERSONALIZED MEDICINE
PRICING STRATEGIES FOR CANCER BIOLOGICS
PERSONALIZED MEDICINE: USING PHARMACOGENOMICS
PHARMACOGENOMICS
TARGETED CANCER THERAPY
LIFESTYLES AND CANCER PREVENTION
MARKETING AND DISTRIBUTION TRENDS
GLOBAL TRENDS
BIOSIMILARS
PATENT EXPIRIES AND BIOSIMILARS
TABLE 85 MAJOR BIOPHARMACEUTICAL PATENT DATES ($ MILLIONS)
BIOSIMILARS AND COSTS OF CANCER DRUGS
BIOGENERICS, BIOSIMILARS AND FOLLOW-ON BIOLOGICS
BIOSIMILAR MANUFACTURERS
BIOSIMILARS IN INDIA AND CHINA
HURDLES FOR BIOSIMILARS
DATA EXCLUSIVITY PERIODS
DIFFERENCES BETWEEN BIOPHARMACEUTICALS AND BIOGENERICS
BIOSIMILARS IN EUROPE
ISSUES WITH BIOSIMILARS
ERYTHROPOIESIS-STIMULATING AGENTS OR ERYTHROPOIETINS (ESAS)
BIOSIMILARS
BIOSIMILARS AND PATIENT SAFETY
CURRENT BIOSIMILARS
SUMMARY
CONCLUSIONS
VENTURE CAPITAL AND RESEARCH INVESTMENT
FUNDING CANCER RESEARCH
TABLE 86 GLOBAL CANCER RESEARCH INVESTMENT, 2009 (MILLIONS/%)
CONCLUSION
CHAPTER 11 COMPANY PROFILES
BIOLOGIC COMPANIES
TABLE 87 GLOBAL BIOLOGIC DRUG PRESCRIPTION SALES, THROUGH 2014 ($ MILLIONS)
SELECTED COMPANIES AND PROFILES
ABBVIE INC.
AMGEN INC.
ASTELLAS PHARMA U.S. LLC
BIOGEN IDEC
BIOSERVICES
BRISTOL MYERS SQUIBB
CELLDEX THERAPEUTICS
CEL-SCI CORP.
DENDREON
ELI LILLY AND COMPANY
GENENTECH INC.
HOFFMANN-LA ROCHE INC.
GENMAB A/S
GENZYME CORP.
GERON CORP.
GLAXOSMITHKLINE
IMMUNOGEN
INOVIO
JOHNSON AND JOHNSON
MERCK & COMPANY
NORTHWEST BIOTHERAPEUTICS
NOVARTIS
NOVARX CORP.
PFIZER
ROCHE/GENENTECH
VICAL INCORPORATED
CHAPTER 12 REFERENCES

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report